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Background and purpose: This study establishes a pharmacokinetic/pharmacodynamic (PK/PD) model to describe the time
course and in vivo mechanisms of action of the antinociceptive effects of lumiracoxib, evaluated by the thermal hyperalgesia
test in rats.
Experimental approach: Female Wistar fasted rats were injected s.c. with saline or carrageenan in the right hind paw, followed
by either 0, 1, 3, 10 or 30 mg·kg-1 of oral lumiracoxib at the time of carrageenan injection (experiment I), or 0, 10 or
30 mg·kg-1 oral lumiracoxib at 4 h after carrageenan injection (experiment II). Antihyperalgesic responses were measured as
latency time (LT) to a thermal stimulus. PK/PD modelling of the antinociceptive response was performed using the population
approach with NONMEM VI.
Results: A two-compartment model described the plasma disposition. A first-order model, including lag time and decreased
relative bioavailability as a function of the dose, described the absorption process. The response model was: LT = LT0/(1 +MED).
LT0 is the baseline response, and MED represents the level of inflammatory mediators. The time course of MED was assumed
to be equivalent to the predicted profile of COX-2 activity and was modelled according to an indirect response model with a
time variant synthesis rate. Drug effects were described as a reversible inhibition of the COX-2 activity. The in vivo estimate of
the dissociation equilibrium constant of the COX-2-lumiracoxib complex was 0.24 mg·mL-1.
Conclusions: The model developed appropriately described the time course of pharmacological responses to lumiracoxib, in
terms of its mechanism of action and pharmacokinetics.
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of COX-2; LT, latency time; LT0, latency time at baseline; MED, inflammatory mediators; NSAID, non-steroidal
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Introduction
Classical non-steroidal anti-inflammatory drugs (NSAIDs) are
the mainstay of therapy for several diseases associated
with inflammation and pain, such as osteoarthritis and
rheumatoid arthritis. Notwithstanding, their long-term use is
associated with gastrointestinal ulceration and serious gas-
trointestinal complications, such as perforation and bleeding
(Hernández-Díaz and García-Rodríguez, 2001). It has been
proposed that NSAIDs-induced gastrointestinal damage
involves local inhibition of the cyclooxygenase-1 (COX-1)
enzyme, which generates cytoprotective prostaglandins in the
gastrointestinal tract (Crofford, 1997; Warner et al., 1999).
The identification of a second isoform of the cyclooxygenase
enzyme, COX-2, which is up-regulated as a result of
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inflammation (Fu et al., 1990), provided the impetus for the
development of COX-2 selective inhibitors. Selective inhibi-
tors of the COX-2 enzyme, referred to as coxibs, were
developed as analgesic and anti-inflammatory agents with
significantly less gastrointestinal toxicity compared with tra-
ditional NSAIDs (Bombardier et al., 2000; Goldstein et al.,
2001). Lumiracoxib is the most selective COX-2 inhibitor
available that has been tested clinically. The relative potency
ratios (COX-2/COX-1) are 433, 344, 272 and 30 for lumira-
coxib, etoricoxib, rofecoxib and celecoxib respectively (Shi
and Klotz, 2008). Unlike other COX-2 inhibitors, which
contain a sulphone group or a sulphonamide group, lumira-
coxib possesses a carboxylic acid group, making it weakly
acidic (Rordorf et al., 2005).
As a result of its chemical structure, lumiracoxib exhibits
moderate clearance. Despite its short half-life (5–8 h), lumira-
coxib is given once daily (Mysler, 2004), suggesting a different
pharmacokinetic/pharmacodynamic (PK/PD) relationship as
compared with other coxibs. Half-life values for etoricoxib,
rofecoxib and celecoxib are 11–16, ~17 and 19–32 h respec-
tively (Ahuja et al., 2003; Shi and Klotz, 2008). Celecoxib is
given twice daily, while rofecoxib and etoricoxib are given
once daily.
There is evidence that lumiracoxib is effective in the treat-
ment of osteoarthritis, rheumatoid arthritis and acute pain
(Rordorf et al., 2005). The onset of lumiracoxib analgesia in
post-operative dental pain is faster than for other coxibs,
although the rate of absorption is similar (Ahuja et al., 2003;
Shi and Klotz, 2008). Pain intensity differences were signifi-
cantly different from placebo at 15, 30 and 60 min for lumira-
coxib, rofecoxib and celecoxib respectively (Kellstein et al.,
2004). On the other hand, there is evidence that lumiracoxib
is readily transferred to inflamed tissues (Weaver et al., 2003).
Thus, it appears that the rapid onset of action of lumiracoxib
is due to a rapid distribution to its effect compartment, rather
than to a rapid absorption. It has been also observed that
lumiracoxib accumulates in inflamed tissues, having a resi-
dence time longer than in plasma allowing a once-daily
dosing (Scott et al., 2004).
PK/PD modelling represents a powerful tool to understand
the in vivo time course of pharmacological effects, providing
insight on the mechanisms of action through the quantitative
description of the pharmacokinetic, pharmacodynamic and
system-related processes (Giraudel et al., 2005). Despite a large
body of scientific literature on the pharmacokinetics and
pharmacodynamics of NSAIDs, information on the integrated
pharmacokinetic–pharmacodynamic profile of these agents is
sparse (Castañeda-Hernández et al., 1995; Flores-Murrieta
et al., 1998; Josa et al., 2001; Huntjens et al., 2005). Further-
more, to our knowledge, for the particular case of coxibs,
there is a lack of studies dealing with the in vivo analysis of
concentration-effect relationships.
Several coxibs have been withdrawn from the market due to
unexpected side effects, including cardiovascular and hepatic
damage. It has been pointed out, however, that such with-
drawals were due to lack of information on PK/PD relation-
ships during the development and assessment of the rationale
for dose selection, which was based on symptomatic relief
rather than on understanding of the degree of COX blockade
required to yield analgesia (Hinz and Brune, 2008).
On the basis of such considerations, the objective of the
current study was to establish a PK/PD model for the analgesic
effects of lumiracoxib in the rat, identifying the rate-limiting
steps in the time course of the response to lumiracoxib, and
characterizing the in vivo concentration-response relation-
ship. To achieve our purpose, we used the thermal hyperalge-
sia test, which has been shown to be a reliable model for the
quantitative assessment of inflammation-induced nocicep-
tion (Hargreaves et al., 1988). We adapted the assay in order to
determine nociception and plasma concentrations in the
same animal, thus allowing characterization of the individual
PK/PD relationship.
Methods
Animals
All animal care and experimental procedures followed the
Guidelines on Ethical Standards for Investigation of Experi-
mental Pain in Animals (Zimmermann, 1983), and the pro-
tocol was approved by the Institutional Animal Care and Use
Committee (Centro de Investigación y de Estudios Avanzados
del Instituto Politécnico Nacional, Mexico City, Mexico).
Female Wistar rats, weighing 180–200 g, were used in this
study. Food was withdrawn 12 h before initiation of experi-
ments, but animals had free access to drinking water. At the
end of the experiments, rats were killed in a CO2 chamber.
Study design
The current study involved two experiments. Briefly, the data
collected in experiment II were used mainly to validate exter-
nally the PK/PD model developed with the data obtained
from experiment I.
Experiment I. Sixty female rats were randomly allocated to six
groups. At the start of the experiment, group I received a
single intraplantar injection of saline solution 0.9% (100 mL)
in the right hind paw, whereas animals in groups II–VI
received a single intraplantar injection of a 1% carrageenan
suspension in 0.9% saline (100 mL). In addition, animals in
groups III–VI were given lumiracoxib orally at the following
doses 1 mg·kg-1 (group III), 3 mg·kg-1 (group IV), 10 mg·kg-1
(group V) or 30 mg·kg-1 (group VI), immediately after the
carrageenan injection. Lumiracoxib was suspended in 0.5%
carboxymethyl cellulose solution and Tween 80 and given in
a volume equal to 4 mL·kg-1.
Blood samples of 200 mL were drawn by means of a cannula
inserted in the caudal artery as previously described (Cruz
et al., 2002). The cannula was inserted 1 h before experi-
ments. Animals were kept restrained between measurements
of hyperalgesia to avoid movement resulting in the removal
of the cannula. Samples were collected at the following times
after drug administration: 0.083, 0.16, 0.25, 0.33, 0.5, 0.75, 1,
2, 3, 4, 6, 8 and 10 h. Each animal contributed four or five
blood samples, taken at times covering uniformly the 10 h
experiment period. A 10 h observation period was chosen on
the basis of pilot experiments and previous pharmacokinetic
data on lumiracoxib pharmacokinetics in the rat (Esser et al.,
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2005a). On the other hand, the antihyperalgesic response
could be reliably followed during 10 h under these experi-
mental conditions.
Lumiracoxib concentrations in plasma and pharmacologi-
cal response were determined as described below. Measure-
ments of the antihyperalgesic effect of lumiracoxib were
performed in the same animals before and 1, 2, 3, 4, 5, 6, 8
and 10 h after saline or carrageenan injection. The pharma-
cological response was determined as described below.
Experiment II. Twenty female rats were divided at random in
three groups. At the start of the experiment, rats received a
single injection of carrageenan as it was described for experi-
ment I. Then, animals received oral vehicle (group VII) or
lumiracoxib at either 10 mg·kg-1 (group VIII) or 30 mg·kg-1
(group IX) 4 h after the injection of carrageenan. Measure-
ments of the antihyperalgesic effect were made before and 1,
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 16, 20 and 24 h after carrag-
eenan injection for each animal.
To summarize the main differences in the experimental
design between experiment I and II: (i) Lumiracoxib was
administered before (experiment I) and during (experiment
II) the development of inflammation, (ii) pharmacokinetics of
lumiracoxib was not studied in experiment II, and (iii) the
period for latency measurement was expanded to 24 h in
experiment II.
Measurement of antinociceptive activity
The animal model of thermal hyperalgesia (Hargreaves et al.,
1988) was used to evaluate the pharmacological effect of
lumiracoxib. A plantar test (Ugo Basile apparatus, Linton
Instrumentation, Comerio, Italy) was used to measure the
withdrawal latencies of the hind paw from a radiant heat
stimulus. Thirty minutes before the start of the experiments,
animals were placed individually in traps to acclimatize them
to the testing environment. Animals were manually placed on
the glass surface, leaving the hind paws uncovered. The
thermal nociceptive stimulus originated from a high-intensity
projector lamp bulb (infrared intensity: 217 mW·cm-2) was
manually manipulated and positioned under the footpad
before and after the plantar injection of saline or carrageenan
into the right hind paw. It has been demonstrated that
lumiracoxib, at the doses used in this study, does not produce
any motor impairment that can interfere with the assay (Ortiz
and Castañeda-Hernández, 2008). The paw withdrawal
latency time (LT), defined as the time required for the paw to
show an abrupt withdrawal, was recorded. In all cases, a
cut-off of 30 s was employed to avoid tissue injury.
Analysis of lumiracoxib in plasma
Blood samples were collected in heparinized tubes and centri-
fuged at 12 400¥ g for 10 min. Plasma samples (100 mL) were
separated and frozen at -70°C until analysis. Lumiracoxib
concentrations in plasma were determined by high-
performance liquid chromatography using ultra violet detec-
tion. The analytical method was developed and validated
previously at the laboratory (data not published). Briefly, 75 mL
of internal standard (30 mg naproxen·mL-1 methanol) was
added to 100 mL of plasma, and 825 mL of methanol was added
to extract the drug by vortex agitation during 5 min at
maximum speed, then samples were centrifuged at 12 400¥ g
during 10 min. An aliquot (60 mL) was injected into the chro-
matographic system equipped with a Novapak C-18 column
(150_3.9 mm ID, particle size 4 mm, Waters Assoc., Milford,
MA, USA) eluted with a mobile phase consisting of a mixture of
acetate buffer (0.035M; pH 3.3) with methanol (62:38 v·v-1) at
constant flow (1.0 mL·min-1) at room temperature. The efflu-
ent from the column was monitored spectrophotometrically at
a wavelength 270 nm. Under these conditions, the naproxen
and lumiracoxib were eluted at retention times 3.21 and
8.34 min respectively. The limit of detection was 0.06 mg·mL-1,
and the quantification limit was 0.10 mg·mL-1. The method was
linear in the range of 0.1–8.0 mg·mL-1 (r2 of 0.9996). At concen-
trations of 0.2, 2 and 7 mg·mL-1, the coefficient of variability
was less than 5% for lumiracoxib.
Data analysis
The time course of LT response was described by a model
integrating the pharmacokinetics and pharmacodynamic
properties of lumiracoxib and the progression of the inflam-
matory response induced by the injection of carrageenan.
The data were analysed based on the population approach
(Beal and Sheiner, 1982; Sheiner and Ludden, 1992) using the
first-order conditional estimation method with the INTERAC-
TION option implemented in the software NONMEM (ICON,
Ellicott City, MD, USA) version VI (Beal and Sheiner, 1989–
2006).
Inter-individual variability (IIV) was modelled exponen-
tially and expressed as coefficient of variation [CV (%)]. Intra-
individual (residual) variability for the case of the plasma
concentration of lumiracoxib (CP) was described with a com-
bined error model, and in the case of the analysis of the LT
response, an additive error model was used.
Model selection was based on a number of criteria, such as
the exploratory analysis of the goodness-of-fit plots per-
formed with Xpose version 4 (University of Uppsala, Uppsala,
Sweden; Jonsson and Karlsson, 1999) programmed in the
statistics package R, the precision of model parameter esti-
mates represented by the coefficient of variation [CV (%)],
computed as the ratio between the standard error provided by
NONMEM and the parameter estimate, and multiplied by
100, and the minimum value of the objective function
(MOFV) provided by NONMEM. The difference in the MOFV
between two hierarchical models was compared with a c2
distribution in which a difference of 6.63 points is significant
at the 1% level for one extra parameter.
The final models were further evaluated using visual pre-
dictive (visual and numerical) checks. Visual predictive check
(Karlsson and Holford, 2008): For each type of measurement
(CP or LT) and experimental group, 1000 time profiles were
simulated using the selected models and the corresponding
parameter estimates. The 2.5, 50, and 97.5th percentiles were
then calculated, and the agreement between simulations and
raw data was inspected visually. Numerical predictive check:
1000 datasets having the same characteristics as the original
dataset were simulated, and for each dataset, the mean CMAX,
maximum concentration of lumiracoxib in plasma, AUC0–last,
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the area under the plasma concentration versus time curve
from time 0 to the last pharmacokinetic measurement, LTmin,
minimum value of LT response, and RedMAX (%), percentage of
maximum reduction in LT with respect to LT0, were com-
puted. Then, the 2.5th and 97.5th percentile and the overall
mean computed from the 1000 simulated studies were calcu-
lated and compared with the same descriptors calculated from
the raw data.
Graphical summaries and simulations were performed in
S-PLUS 6.2. professional edition software (Copyright 1988,
2002 Insightful Corp., Seattle, WA, USA).
Pharmacokinetic modelling. The pharmacokinetics of lumira-
coxib in plasma was described by compartmental models
parameterized in terms of an apparent volume of distribution,
inter-compartmental clearance, and total clearance. Different
models were also fitted to the data to characterize the absorp-
tion process: zero and first order rate models, with or without
the presence of a lag time. The effect of the dose was explored
in all the pharmacokinetic parameters, including relative bio-
availability (Frel) (Josa et al., 2001).
Pharmacokinetic/pharmacodynamic modelling. The different
models fitted to the LT response versus time data are described
in the results section. Here we focus on the description of the
final selected model, which appears schematically in Figure 1.
The model has the following general form:
LT
LT
MED
t
t
=
+
0
1
(1)
where LTt is the latency response at time t, LT0, is the baseline
LT, and MEDt, corresponds to the unobserved level of inflam-
matory mediators in the damaged tissue as a consequence of
the presence of the enzyme COX-2 in its active form (COX-
2_act; see below in equation 4). The initial condition for MED is
0, and consequently, at the start of the experiment, LT = LT0.
An increment in MEDt will lead to a decrease in LT reflecting
the phenomena of hyperalgesia.
The time course of (unobserved) COX-2 was modelled as
follows:
d
dt
COX-
k k COX-S_COX- t D_COX-
2
22 2= − ×( ) (2)
where dCOX-2/dt is the rate of change of the enzyme
COX-2, kS_COX-2 t( ) and kD_COX-2 represent the synthesis and
degradation processes of the enzyme COX-2 respectively
(Dayneka et al., 1993). At the start of the study, COX-2 and
kS_COX-2 t( ) were assumed to be 0. Such an assumption is based
on published data where the expression of COX-2 protein and
prostaglandin E2 (PGE) peripheral tissue levels before an
inflammatory stimulus was found to be less than 1% com-
pared with post-inflammation (Nantel et al., 1999).
The synthesis of COX-2 induced by the injection of carra-
geenan was not assumed to be constant over the period of the
study. Accordingly, different models accounting for a linear or
a non-linear increase or decrease in kS_COX-2 t( ) with time were
fit to the data. In particular, a gamma function (Wise, 1985;
Giraudel et al., 2005) was explored to describe the time course
of kS_COX-2 t( ) :
kS_COX-2 t A e
t t
( ) = × ×
− ×α β (3)
where A, a and b are the parameters of the gamma function
describing the time course and intensity of the COX-2 syn-
thesis rate.
Drug effects were incorporated in the model assuming that
lumiracoxib reversibly blocks (inactivates) COX-2, preventing
MED recruitment, and therefore reversing hyperalgesia:
COX-
COX-
act
D
D P
2
2
=
×
+
K
K C
(4)
KD is the equilibrium dissociation constant of the COX-2-CP
complex (COX-2_inactive). In equation (4), the total plasma
COX-2
kS_COX-2(t)
kD_COX-2
Latency
Response
MED
-
Arachidonic
acid+
CP Central
Vc
Peripheral
VT
Depot
KA, Tlag, Frel
CL
Q
Figure 1 Schematic representation of the PK/PD model selected to describe the data for experiments I and II. CP, concentration of lumiracoxib
in plasma; COX-2, arbitrary levels of active COX-2; Frel, relative bioavailability; KA, first-order rate constant of absorption; kD_COX-2, first-order rate
constant of degradation of COX-2; kS_COX-2, time variant zero-order rate constant of synthesis of COX-2; PK/PD, pharmacokinetic/
pharmacodynamic Tlag, lag time; MED, inflammatory mediators; Q, and CL, inter-compartmental and elimination clearances respectively; Vc
and VT, apparent volumes of distribution in the central and peripheral compartments respectively.
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concentrations of lumiracoxib are used and the free fraction is
not considered. It is assumed that between arachidonic acid
and lumiracoxib, a competitive interaction occurs, and that
the concentration of arachidonic acid in the effect site
remains unchanged during the study.
Assuming that COX-2_inactive = COX-2 - COX-2_act, equa-
tion (4) is derived after rearrangement of the terms presented
previously.
In absence of lumiracoxib, all COX-2 synthesized is in the
activated form [COX-2_act = COX-2]. In equation (4), CP rep-
resents the predicted plasma level provided by the selected
population pharmacokinetic model.
Finally, in equation (1), the time course of MED has been
assumed to be identical to the time course of COX-2_act. Such
assumption represents a limitation in the proposed model,
since suppression of downstream mediators may not occur
concurrently to COX-2 itself.
The model represented by equations (1)–(4) was selected
from the data from experiment I and was used to describe the
data in experiment II using the visual predictive check.
Finally, all model parameters were re-estimated using all LT
data obtained from the two experiments.
Statistical analysis
Results from experiments I and II after injection of saline or
carrageenan in the control and treated groups with lumira-
coxib are shown as mean data with their corresponding stan-
dard deviations. One-way analysis of variance, followed by
Tukey’s test was used to compare differences between treat-
ments. Statistical significance was considered to be achieved
when P < 0.05.
Materials
Lumiracoxib was provided by Novartis Farmacéutica, S.A.
(Mexico City, Mexico). Naproxen was supplied by Grupo
Roche-Syntex de México S.A. (Mexico City, Mexico). Carrag-
eenan was purchased from Sigma Chemical Co. (St. Louis,
MO, USA). Methanol, chromatographic grade, was purchased
from Merck (Darmstadt, Germany). All other reagents and
solvents used were purchased from commercial sources and
were of analytical grade.
Results
Data description
Figure 2 shows the mean time profiles obtained from experi-
ments I and II. In the upper panel, the observed PK profiles are
represented. Maximum concentrations of lumiracoxib in
plasma appeared within the two first hours after drug admin-
istration, with mean values of 0.33  0.02, 0.94  0.12, 1.45
 0.16 and 3.64 0.25 mg·mL-1 for the 1, 3, 10 and 30 mg·kg-1
dose groups, respectively, suggesting dose-dependent
pharmacokinetics.
All groups showed mean baseline LT ranging between 12
and 17 s (Figure 2, middle and lower panels), and a statistical
analysis did not provide significant differences at baseline
between groups I and IX (P > 0.05). The injection of saline
elicited a slight but significant decrease in the LT response
compared with the baseline LT (P < 0.05). Injection of carra-
geenan produced a significant decrease in LT reaching the
maximum at 3 h after injection (P < 0.05). In the case of
experiment II, it can be observed that after 24 h, the LT
response returned to its original value.
Lumiracoxib exerted a dose-dependent effect. The profiles
shown in the middle panel of Figure 2 suggest that the two
lowest doses (1 and 3 mg·kg-1) were not high enough to revert
significantly the carrageenan-induced hyperalgesia (P > 0.05).
On the other hand, the doses of 10 and 30 mg·kg-1 elicited
significant antinociceptive response (P < 0.05).
Pharmacokinetic modelling
Disposition of lumiracoxib in plasma was best described by a
two-compartment model. This model behaved significantly
better that the one-compartment model (P < 0.01), and
the three-compartment model did not show a significant
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Figure 2 Time course of plasma concentrations of lumiracoxib
(panel A). Time course of the latency response versus time profiles
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panels B and C, data from rats injected with saline (control) or with
carrageenan only (CG) are shown, as well as data from rats given
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improvement (P > 0.05) over the selected model. The data
allowed the estimation of IIV in Vc, the apparent volume of
the central compartment, and CL, total plasma elimination
clearance (P < 0.01).
A first-order rate of absorption model including a lag time
(Tlag) was found an adequate model to describe the absorption
process. IIV was also estimated for the first-order rate of
absorption (KA) and Frel (P < 0.01).
Dose showed statistical significant effects on Frel (P < 0.01)
but not on the other PK model parameters (P > 0.05). An
increase in the administered dose was associated with a
decrease in Frel. The relationship between Frel and dose was
incorporated in the model using the expression represented
in Table 1. The model predicts a maximum dose-elicited
decrease in Frel of approximately 30%.
The estimates of the selected model are listed in Table 1.
Results indicate that parameters were estimated in general
with good precision. Individual observations corresponding
to three rats in each dose group are represented in Figure 3,
together with their individual model predicted profiles, where
it can be observed that the predictions from the model
matches the observed data very well. Supplementary informa-
tion (Figure S1) shows several goodness of fit plots obtained
from the selected PK model. Those plots indicate that model
mis-specifications are minor.
Selection of the final model was further supported by the
predictive checks. In Table 2, the results from the numerical
predictive check are listed. With the exception of CMAX for the
3 mg·kg-1 dose group, the rest of mean values calculated from
the raw data fall within the 2.5th–97.5th percentiles of the
model-based simulated data.
Pharmacokinetic/pharmacodynamic modelling
The indirect response model accurately characterized the
analgesic profiles following administration of lumiracoxib.
For example, Figure 4 shows the results for the visual predic-
tive check (lines in red) obtained from the model developed
Table 1 Parameter estimates from the final population pharmaco-
kinetic model
Parameter Estimate IIV (%)
CL (L·h-1) 0.16 (14) 36 (43)
Vc (L) 0.49 (9) 39 (27)
Q (L·h-1) 0.42 (12) –
VT (L) 0.99 (19) –
kA (h-1) 15.2 (23) 92 (30)
Tlag (h) 0.06 (10) –
F I
D
D D
rel MAX= − ×
+
⎡
⎣⎢
⎤
⎦⎥1 50
IMAX 0.67 (6)
D50 (mg·kg-1) 4.3 (43)
18 (60)
Residual error
Additive (mg·mL-1) 0.037 (20) –
Proportional (%) 22 (10) –
Parameter estimates are listed together with the coefficient of variation [CV
(%)] in parenthesis.
CL, apparent plasma clearance;D50, dose of lumiracoxib eliciting a decrease in Frel
equal to half of IMAX; Frel, relative bioavailability; IIV, inter-individual variability, is
expressed as CV (%); IMAX, maximum fractional reduction in Frel that the dose
level of lumiracoxib (D) can exert; Vc and VT, apparent volumes of distribution of
the central and peripheral compartments respectively; Q, inter-compartmental
clearance; KA, first-order rate constant of absorption; Tlag, lag time.
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Figure 3 Individual lumiracoxib plasma concentrations versus time profiles from three rats. The symbols represent the individual raw data,
and the lines, the predictions from the model.
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with the data from experiment I, where all groups (including
those from experiment II) are described properly. Model
parameter estimates are listed in Table 3 (middle columns). LT
response data supported the inclusion of IIV on LT0 and KD
only (P < 0.01), and not in the rest of the model parameters
(P > 0.05).
During the model development process, the incorporation
of an effect compartment (Sheiner et al., 1979) accounting for
the delay in lumiracoxib distribution between the central
and the effect compartment was not supported by the data
(P > 0.05). The assumption of reversible inhibition of kS_COX-2(t)
increased the minimum value of the objective function by
eight points for the same number of parameters, indicating a
worse fit. Therefore, the model structure was based on a
reversible competition between lumiracoxib and arachidonic
acid for the binding to COX-2 (equation 4). In addition, the
inclusion of a sigmoidicity parameter in equation 4 was not
statistically significant (P > 0.05).
The dynamics of the synthesis of the unobserved COX-2
during the period of the experiments was evaluated in detail,
fitting both time-constant and time-variant models to the
data. Other models fitted to the data to describe the course of
kS_COX-2 t( ) (i.e. linear or exponential decay with time) described
the observations significantly worse than the selected model
using the gamma function (equation 3) (P < 0.01). For the case
of group I, where only saline was injected, data suggested a
constant rate of synthesis; however, for those groups of
animals receiving carrageenan, the model represented by
equation 2 was significantly better (P < 0.01).
When all LT response data from experiments I and II were
pooled and analysed together, parameter estimates remained
almost unchanged, but their precision was improved (Table 3,
right column).
Individual observations corresponding to two rats in each
dose group are represented in Figure 5 together with their
individual model predicted profiles, where it can be observed
Table 2 Results from the predictive check obtained from 1000 simulated studies based on the selected population pharmacokinetic model
Dose (mg·kg-1) CMAX (mg·mL-1) AUC0–last (mg ¥ h ¥ L-1)
Observed Simulated Observed Simulated
1 0.33 0.31 [0.26–0.38] 0.2 0.18 [0.15–0.22]
3 0.94 0.68 [0.56–0.80] 1.23 0.94 [0.84–1.04]
10 1.45 1.65 [1.35–2.0] 3.63 3.7 [3.31–4.12]
30 3.64 3.94 [3.23–4.63] 9.4 8.7 [7.82–9.61]
Data in the table are expressed as means, with 2.5th and 97.5th percentiles in brackets.
AUC0–last, area under the plasma concentration curve calculated from time 0 to last pharmacokinetic measurement time; CMAX, maximum plasma concentration.
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that the model describes the data very well. Supplementary
information (Figure S2) shows several goodness of fit plots
obtained from the selected model. Those plots indicate that
model mis-specifications are minor.
Selection of the final model was further supported by the
predictive checks. Figure 4 represents also the results from
the visual predictive check (lines in blue) corresponding to
the model and parameter estimates obtained from the
simultaneous fit of data from experiment I and II. It can be
seen that the model describes properly both, the mean ten-
dency and the dispersion in the data for all the dose groups,
and that model predictions obtained from the two sets of
parameters listed in Table 3 are almost indistinguishable.
In Table 4, the results from the numerical predictive check
are listed. With the exception of RedMAX(%) for the 1 mg·kg-1
dose group, the rest of mean values calculated from the raw
data fall within the 2.5th–97.5th percentiles of the model-
based simulated data.
Figure 6 shows, in the left panel, the typical model pre-
dicted time profiles of COX-2 in group I and in groups which
received carrageenan. The right-hand panel in Figure 6 repre-
sents the concentration versus effect relationship for lumira-
coxib reflected in equation 4 and corresponds to an estimate
of KD of 0.24 mg·mL-1 (Table 3).
Discussion and conclusions
In this work, a PK/PD model was developed for the antinoci-
ceptive effects of lumiracoxib in an animal model of hyper-
algesia, fulfilling therefore the primary objective of the
current study.
The plantar test has been used to assess the hindpaw
nociceptive withdrawal latencies to thermal stimuli in rats
(Hargreaves et al., 1988). This test is a simple, rapid and sen-
sitive method suitable for detecting peripheral hyperalgesia in
rats (Hargreaves et al., 1988). Despite differences in the
response to different classes of pharmacological agents, this
Table 3 Parameter estimates from the final population pharmaco-
dynamic models selected by experiment I and experiment I and II
Parameter Experiment I Experiment I and II
Estimate IIV (%) Estimate IIV (%)
kS_COX-2 (COX-2·h-1)a 0.20 (62) – 0.21 (38) –
A (COX-2·h-2) 1.32 (24) – 1.42 (15) –
a 1.07 (29) – 1.3 (21) –
b (h-1) 0.27 (22) – 0.33 (17) –
kD_COX-2 (h-1) 0.72 (68) – 0.89 (39) –
KD (mg·mL-1) 0.33 (24) 33 (126) 0.24 (21) 62 (54)
LT0 (s) 15.1 (3) 13 (28) 14.3 (3) 13 (33)
Residual error (s) 2.6 (9) – 2.4 (10) –
Parameter estimates are listed together with the coefficient of variation [CV
(%)] in parenthesis. IIV, inter-individual variability, is expressed as CV (%);
kS_COX-2 t( ) and kD_COX-2 represent the synthesis and degradation processes of the
enzyme COX-2. A, a and b are the parameters of the gamma function describ-
ing the time course and intensity of the COX-2 synthesis rate in the groups
injected with carrageenan. KD is the equilibrium dissociation constant of the
COX-2-CP complex, where CP, is refers to the concentration of lumiracoxib in
plasma. LT0, paw withdrawal latency time at baseline.
aEstimate of kS_COX-2 corresponding to the group receiving saline.
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end point is clearly sensitive to the COX-2 selective inhibitor
lumiracoxib.
As it can be appreciated in Figures 2 and 4, lumiracoxib was
not able to completely reverse carrageenan-induced hyperal-
gesia. That result, however, should be expected if the hyper-
algesic response was solely due to the mediators produced by
COX-2. It is now known that in several models of inflamma-
tion in the rat, platelet COX-1 activity can be a source of
inflammatory mediators, such as PGE2 (Giuliano and Warner,
2002). Moreover, Wallace et al. (1998; 1999) have reported
that certain COX-2 inhibitors need to be administered at
non-selective, COX-1-inhibiting doses to abolish the inflam-
matory response in the carrageenan-induced paw-oedema or
the air pouch model. As lumiracoxib is extremely selective for
COX-2, it is unlikely that platelet COX-1 activity was affected
at the doses used in our study. Hence, lumiracoxib produces
only a partial inhibition of the hyperalgesic response.
Pharmacokinetic model
In the present study, a two-compartmental model was
selected, which is consistent with previous preclinical results,
where the PK of lumiracoxib was investigated (Esser et al.,
2005a). A high bioavailability was assumed, which is a rea-
sonable assumption given the fact that the drug was admin-
istered as a suspension, and the low estimated clearance.
Rordorf et al. (2005) reported a value of 0.74 for the absolute
bioavailability in humans when lumiracoxib was adminis-
tered in tablets.
Relative bioavailability was found to be dose dependent,
with a typical value for the highest dose administered ~30%
lower than the corresponding to the lowest dose level studied.
Similar results were found by Rordorf et al. (2005) in humans,
where the CMAX did not increase proportionally with the
increase in dose. It is also worth noting that a very similar
finding has been seen for the NSAID naproxen (Josa et al.,
2001). It is difficult to provide a mechanism explaining the
dose-dependent decrease in relative bioavailability given the
data available. This could be due to the limited solubility of
the drug, but further investigation is required to fully eluci-
date this issue.
COX-2 model
Intra-plantar injection of carrageenan induces a transient
increase in COX-2 activity. Seibert et al. (1994) and Nantel
et al. (1999) reported that COX-2 mRNA was just detectable
within 60 min, with a substantial induction observed at 3 h
after injection of carrageenan in the paw. In the current evalu-
ation, the (unobserved) time course of COX-2 activity was
modelled empirically using the gamma function used by
Giraudel et al. (2005) to describe the effects of meloxicam in
Table 4 Results from the predictive check obtained from 1000 simulated studies based on the selected population pharmacokinetic/
pharmacodynamic model
Dose (mg·kg-1) LTMIN (s) RedMAX (%)
Observed Simulated Observed Simulated
Saline 8.1 8.3 [7.4–9.4] 45 42.5 [38–48]
Carrageenana 1.9 1.6 [0.8–2.4] 87 89 [84–95]
1 3.3 2.3 [1.5–3.2] 75 84 [78–89]
3 3.9 3.05 [2.2–4] 76 79 [73–86]
10 5.3 4.4 [3.2–5.6] 67 70 [63–77]
30 6.5 6 [4.9–7.1] 57 58 [52–66]
10b 3 2.6 [1.5–3.8] 73 82 [75–90]
30b 3.5 3 [1.8–4.3] 73 79 [71–88]
Data in the table are expressed as means, with 2.5th and 97.5th percentiles in brackets.
aData from experiment I and II combined.
bDose groups corresponding to experiment II.
LTMIN, minimum latency response; RedMAX, maximum percentage reduction in latency response with respect to baseline.
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an inflammation model in cats. Interestingly, the estimates of
the gamma function reported by us are of the same order than
those shown by Giraudel et al. (2005), and provided a very
good description of the control groups. The typical COX-2
profile shown in Figure 6 (right panel) resembled very closely
the experimental data reported by Seibert et al. (1994) and
Jain et al. (2008).
Pharmacodynamic model
It is well known that selective COX-2 inhibitors exert their
pharmacological action through a reversible inhibition of
COX-2, hampering the formation of the COX-2-arachidonic
acid complex and therefore decreasing the synthesis of
inflammatory mediators, such as prostaglandins (Vane, 1971).
However, and to the best of our knowledge, previous studies
on the PK/PD modelling of the effects of NSAIDs incorporate
the drug action as an inhibition (INH) of the synthesis rate of
inflammation mediators (kin), (Trocóniz et al., 2000; Josa et al.,
2001; Giraudel et al., 2005) as follows: dR/dt = kin ¥ INH - kout
¥ R, where dR/dt is the rate of change of inflammation media-
tors or the measured response (R), and kout being the first-order
rate of degradation.
The model selected in the current study resembled better
the known mechanism of action of the NSAIDs, as the drug
does not affect the rate of synthesis of COX-2, but competes
reversibly with arachidonic acid for binding to COX-2. The
selected model provided a better fit to the data in comparison
to the rate inhibition model, and described the time course of
the latency response in all the dose groups. It should be taken
into account that the pharmacodynamic model used in this
analysis is based on the receptor occupancy theory and
assumes a linear transduction function, which might not be
the case, as it has been shown when the operational model of
agonism (Black and Leff, 1983) has been applied to different
classes of drugs (Van der Graaf et al., 1997; 1999). The data
available in this work do not support the investigation of
more complex pharmacodynamic models, which requires the
integration of information obtained from different com-
pounds of the same class (Van der Graaf and Danhof, 1997).
The estimates obtained for the pharmacodynamic param-
eters are difficult to compare across different studies because
of the different designs and different types of measured
response, and the lack of PK/PD results for this particular
drug. The estimate obtained for KD 0.24 mg·mL-1 (0.81 mM), is
too high compared with results obtained from in vitro binding
experiments, where IC50 has been estimated to be 17 ng·mL-1
(60 nM) (Esser et al., 2005b). It should be noted that the IC50
values reported in the literature refer only to the inhibition of
PGE2 production by lumiracoxib (Esser et al., 2005a,b; Rordorf
et al., 2005). COX-2, however, does not only produce PGE2
and other prostaglandins. COX-2 activity results in the syn-
thesis of a variety of mediators involved in the hyperalgesic
response. This is why we preferred to express the products of
COX-2 as MED. MED refers to all the mediators generated by
COX-2 activity involved in the hyperalgesic response. Thus,
our KD value refers to total COX-2 activity, and not only to
PGE2 production.
Notwithstanding, it should be noted that the in vivo situa-
tion is considerably different from that in vitro. Our KD
estimates correspond to total lumiracoxib plasma concentra-
tion. It is known that lumiracoxib is bound extensively (about
98%) to human plasma proteins (Rordorf et al., 2005). There is
evidence that plasma protein binding is similar in several
mammalian species, including human, monkey and rat
(MHRA Medicines and Healthcare Products Regulatory
Agency, 2005). Thus, considering the unbound lumiracoxib
concentration, the KD value is 16 nM, being in the range of
previously reported values in vitro.
It has been reported that lumiracoxib is not only a COX-2
inhibitor, as it also exhibits activity as a thromboxane receptor
antagonist in the micromolar concentration range (Selg et al.,
2007). There is evidence that thromboxane receptors are
involved in inflammation (Thomas et al., 2003) and could
contribute to nociception (Evans et al., 2000) in certain assays.
Nonetheless, to our knowledge, there is no available evidence
that thromboxane receptors play a role in the Hargraves
model of thermal hyperalgesia. Therefore, we preferred to
limit our pharmacodynamic model to lumiracoxib actions on
COX-2, which explain reasonably well the experimental data.
It has been shown that the metabolite 4′-hydroxy-
lumiracoxib exhibits pharmacological activity in vitro, having
similar potency and COX-2 selectivity to the parent molecule
(Mangold et al., 2004). Notwithstanding, plasma concentra-
tions of 4′-hydroxy-lumiracoxib in vivo are much lower than
those of lumiracoxib (Rordorf et al., 2005). Those findings,
together with the fact that no dose dependency was found for
the KD parameter in the current study, suggest that, under the
experimental conditions used in the current study, the role of
4′-hidroxy-lumriacoxib on the analgesic effects is negligible.
The robustness of the model was confirmed both by the
accuracy of the estimates for latency response when lumira-
coxib was administered at the time of maximum rate of syn-
thesis of COX-2 and by predictions of the latency response
beyond the experimental window in experiment I.
In conclusion, the use of PK/PD modelling enables accurate
assessment of the analgesic response, taking into account the
underlying pharmacological mechanisms. As illustrated for
lumiracoxib, this approach yields parameters describing drug
properties in a dose-independent manner. It is anticipated
that PK/PD modelling can provide a more robust rationale for
dose selection of COX-inhibitors in humans.
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